Revlimid, an immunomodulatory drug, and Velcade, a proteasome inhibitor, play key roles as the backbone for combination regimens across various lines of therapy. These drugs have broad approvals in all markets, and the launch of generics in 2022 will, over time, exert substantial downward pressure on the MM market. 

The launches of BCMA-targeted therapies will play a pivotal part in future market dynamics over the next decade. Key anti-BCMA agents include the CAR-T therapies Abecma and Carvykti, which are approved for fifth-line or later MM in the US and for fourth-line or later MM in the EU. Given the unmet need for effective therapies for heavily pretreated patients, demand has been high and manufacturing has struggled to keep pace. 

This Datamonitor Healthcare report contains a Disease Analysis module.